Implantica (IMP) Q2 2025 earnings summary

Executive summary

• Five-year pivotal study results for RefluxStopⓇ published, showing superior outcomes and safety, with high patient satisfaction and no device-related adverse events.

• Final FDA PMA module submitted; FDA feedback expected by September, inspections scheduled for October, and U.S. approval targeted for late 2024 or 2025.

• NICE endorsement in the UK enables broader NHS access, with first National Users Meeting and guidance for IOM/IEM patients, supporting wider adoption.

• Over 1,300 surgeries performed in the EU, with Spain as the fastest-growing region and 19 hospitals adopting RefluxStopⓇ.

• U.S. launch preparations include new production facility, over 10,000 devices ordered, and strong surgeon interest post-approval.

Financial highlights

• Q2 net sales were €433k, down 22% year-over-year, mainly due to patient accumulation for a new randomized clinical trial; H1 net sales rose 2% to €1.18m.

• Adjusted gross margin for Q2 was 90% (vs. 91% prior year); H1 margin improved to 94% (from 91%).

• Q2 operating loss (EBIT) improved by 23% to €4.53m; H1 EBIT loss reduced by 33% to €8.70m, driven by lower R&D costs.

• Cash and short-term investments totaled €56.3m at period end, with no interest-bearing debt.

• Shareholders' equity at €92.8m as of June 30, 2025; equity ratio increased to 98%.

Outlook and guidance

• FDA approval for RefluxStopⓇ anticipated late 2024 or 2025, with U.S. launch preparations and production ramp-up underway.

• Revenue in Europe expected to accelerate as reimbursement improves, especially in the UK and Spain.

• Randomized controlled trial (RCT) for RefluxStopⓇ versus Nissen fundoplication launched, with results expected within 1–1.5 years.

• Expansion plans include scaling from 50 to 500+ centers in the U.S. and further global market penetration.

• Revenue impact from RCT launch expected to ease as patient recruitment stabilizes.